China
· Delayed Price · Currency is CNY BeiGene Statistics
Total Valuation
BeiGene has a market cap or net worth of CNY 214.79 billion. The enterprise value is 203.54 billion.
| Market Cap | 214.79B |
| Enterprise Value | 203.54B |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.86% |
| Shares Change (QoQ) | +1.23% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 74.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 8.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -43.25 |
| EV / Sales | 7.35 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -44.03 |
Financial Position
The company has a current ratio of 1.80, with a Debt / Equity ratio of 0.32.
| Current Ratio | 1.80 |
| Quick Ratio | 1.51 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.71 |
| Interest Coverage | -38.61 |
Financial Efficiency
Return on equity (ROE) is -18.77% and return on invested capital (ROIC) is -8.01%.
| Return on Equity (ROE) | -18.77% |
| Return on Assets (ROA) | -6.07% |
| Return on Invested Capital (ROIC) | -8.01% |
| Return on Capital Employed (ROCE) | -15.35% |
| Revenue Per Employee | 2.53M |
| Profits Per Employee | -427,851 |
| Employee Count | 11,000 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.30 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +89.83% in the last 52 weeks. The beta is 0.65, so BeiGene's price volatility has been lower than the market average.
| Beta (5Y) | 0.65 |
| 52-Week Price Change | +89.83% |
| 50-Day Moving Average | 212.39 |
| 200-Day Moving Average | 166.65 |
| Relative Strength Index (RSI) | 69.88 |
| Average Volume (20 Days) | 2,536,349 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.52 |
Income Statement
In the last 12 months, BeiGene had revenue of CNY 27.81 billion and -4.71 billion in losses. Loss per share was -44.70.
| Revenue | 27.81B |
| Gross Profit | 23.48B |
| Operating Income | -4.15B |
| Pretax Income | -3.89B |
| Net Income | -4.71B |
| EBITDA | -2.93B |
| EBIT | -4.15B |
| Loss Per Share | -44.70 |
Balance Sheet
The company has 19.18 billion in cash and 7.88 billion in debt, giving a net cash position of 11.30 billion.
| Cash & Cash Equivalents | 19.18B |
| Total Debt | 7.88B |
| Net Cash | 11.30B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 24.32B |
| Book Value Per Share | 227.91 |
| Working Capital | 12.97B |
Cash Flow
In the last 12 months, operating cash flow was -1.03 billion and capital expenditures -3.60 billion, giving a free cash flow of -4.62 billion.
| Operating Cash Flow | -1.03B |
| Capital Expenditures | -3.60B |
| Free Cash Flow | -4.62B |
| FCF Per Share | n/a |
Margins
Gross margin is 84.41%, with operating and profit margins of -14.93% and -16.92%.
| Gross Margin | 84.41% |
| Operating Margin | -14.93% |
| Pretax Margin | -13.99% |
| Profit Margin | -16.92% |
| EBITDA Margin | -10.55% |
| EBIT Margin | -14.93% |
| FCF Margin | n/a |
Dividends & Yields
BeiGene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.86% |
| Shareholder Yield | -0.86% |
| Earnings Yield | -2.19% |
| FCF Yield | -2.15% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BeiGene has an Altman Z-Score of 2.93. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.93 |
| Piotroski F-Score | n/a |